Mandelic AcidvsTranexamic Acid

Mandelic acid (152 Da, the largest common AHA) exfoliates through calcium chelation and corneodesmosome disruption like other AHAs, but its large molecular size results in slower, more even epidermal penetration with reduced risk of hot-spot irritation and stratum corneum over-exfoliation. Its phenyl ring confers partial lipophilicity, enabling penetration into the pilosebaceous unit and follicular infundibulum—unlike purely hydrophilic glycolic and lactic acids. Within pores, mandelic acid exerts mild comedolytic effects by disrupting keratinocyte cohesion in the follicular epithelium, similar to salicylic acid. It demonstrates antibacterial activity against Cutibacterium acnes (Propionibacterium acnes) through membrane disruption. Mandelic acid also inhibits tyrosinase and reduces melanosome transfer to keratinocytes, providing brightening benefits. This profile makes it particularly suitable for acne-prone skin, hyperpigmentation, and darker skin tones (Fitzpatrick IV–VI) where gentler exfoliation minimizes post-inflammatory hyperpigmentation risk.

Tranexamic acid (TXA) is a lysine analogue that competitively inhibits plasminogen activation—binding lysine-binding sites and preventing conversion to plasmin by tPA and uPA. Plasmin normally activates multiple pathways: converts latent TGF-beta to active form, stimulates keratinocyte release of arachidonic acid and prostaglandins (PGE2, PGF2-alpha), and increases SCF and bFGF—all stimulating melanocyte proliferation and melanogenesis. By blocking plasmin, TXA interrupts this paracrine cascade, reducing melanin through a mechanism independent of tyrosinase. TXA also inhibits VEGF and reduces angiogenesis—addressing melasma's vascular component. May reduce UV-induced plasmin in keratinocytes. This unique mechanism makes TXA synergistic with tyrosinase inhibitors for stubborn melasma.